

Financial news for CHRS dated on 2020-05-07: Coherus BioSciences Q1 EPS \$0.480 Misses \$0.560 Estimate, Sales \$116.180M Miss \$119.520M Estimate

Financial news for CHRS dated on 2020-04-17: Coherus BioSciences shares are trading higher after SunTrust Robinson Humphrey initiated coverage on the stock with a Buy rating and a price target of \$26 per share.

Financial news for CHRS dated on 2020-04-17: SunTrust Robinson Humphrey Initiates Coverage On Coherus BioSciences with Buy Rating, Announces Price Target to \$26

Financial news for CHRS dated on 2020-04-13: Coherus Warns 'There are reasons to expect that the adverse effects we are experiencing and expect to continue to experience from COVID-19' In Q2, H2'20

Financial news for CHRS dated on 2020-04-13: Coherus Reports Pegfilgrastim Class Unit Growth During Last 4 Weeks Of Mar. Up 6% Month Over Month, UDENYCA Unit Growth 7%

Financial news for CHRS dated on 2020-04-13: Coherus Biosciences Sees Q1 Sales \$115M-\$117.5M vs \$118.9M Estimate, Net Income \$33.5M-\$38M

Financial news for CHRS dated on 2020-03-27: Shares of several healthcare companies are trading lower, selling off from this week's strength. While the US stimulus package boosted economic optimism, demand concerns still exist amid the coronavirus outbreak.

Financial news for CHRS dated on 2020-03-05: Coherus BioSciences Reports Its US Manufacturing, Distribution Is Well Positioned To Ensure Uninterrupted Availability Of UDENYCA For Patients

Financial news for CHRS dated on 2020-02-28: H.C. Wainwright Reiterates Buy on Coherus BioSciences, Raises Price Target to \$30

Financial news for CHRS dated on 2020-02-27: Coherus BioSciences Q4 EPS \$0.53 Misses \$0.72 Estimate, Sales \$123.856M Beat \$123.01M Estimate

Financial news for CHRS dated on 2020-02-06: JP Morgan Maintains Overweight on Coherus BioSciences, Raises Price Target to \$35

Financial news for CHRS dated on 2020-01-13: Coherus BioSciences Acquires the Commercial Rights for Avastin in the United States, Will Pay Up to \$45M in Milestones

Financial news for CHRS dated on 2019-11-07: Coherus BioSciences shares are trading higher. The company on Wednesday reported Q3 results and acquired the rights to commercialize Bioeq's biosimilar candidate Lucentis.

Financial news for CHRS dated on 2019-11-07: Citigroup Maintains Buy on Coherus BioSciences, Raises Price Target to \$31

Financial news for CHRS dated on 2019-11-06: Coherus BioSciences Q3 EPS \$0.63 Beats \$0.51 Estimate, Sales \$111.68M Beat \$101.37M Estimate

Financial news for CHRS dated on 2019-11-06: Coherus Acquires Rights to Commercialize Bioeq's Biosimilar Candidate to Lucentis in the US for a 'Mid-Single Million Dollar' Upfront Payment

Financial news for CHRS dated on 2019-11-05: Coherus BioSciences shares are trading lower. Not seeing any news to justify the price action.

Financial news for CHRS dated on 2019-10-22: Coherus BioScience shares are trading lower despite no company specific news. The stock has dropped approximately 23% over the past month.

Financial news for CHRS dated on 2019-10-09: Coherus BioSciences shares are trading lower. Not seeing any news to justify the price action.

Financial news for CHRS dated on 2019-10-04: Coherus Biosciences shares are trading higher. Not seeing any news to justify price action.

Financial news for CHRS dated on 2019-09-25: Coherus BioSciences Shares Fall 6% Over Last Min., Still Up 1% for Session

Financial news for CHRS dated on 2019-08-13: Mizuho Initiates Coverage On Coherus BioSciences with Buy Rating, Announces \$43 Price Target

Financial news for CHRS dated on 2019-08-12: Coherus Biosciences Shares Quiet After Hours As Hearing Mizuho Initiated Coverage With A Buy Rating And \$43 Price Target

Financial news for CHRS dated on 2019-08-02: Coherus BioSciences Late Thursday Reported Q2 EPS \$0.32 Beat \$0.08 Estimate, Sales \$83.433M Beat \$75.49M Estimate

Financial news for CHRS dated on 2019-07-29: Dismissal of Amgen's Patent Infringement Lawsuit Against Coherus Biosciences is Upheld by the US Appeals Court

Financial news for CHRS dated on 2019-07-08: Coherus BioSciences Sees Prelim. Q2 UDENYCA Net Sales Of \$79M-\$84M

Financial news for CHRS dated on 2019-07-01: Coherus BioSciences Reports Produced 400K+ UDENYCA Pre-Filled Syringes To Date

Financial news for CHRS dated on 2019-06-11: Coherus BioSciences shares are trading higher after Barclays initiated coverage on the company's stock with an overweight rating and a \$30 price target.

Financial news for CHRS dated on 2019-06-11: Barclays Initiates Coverage On Coherus BioSciences with Overweight Rating, Announces \$30 Price Target

Financial news for CHRS dated on 2019-05-09: Coherus BioSciences Q1 EPS \$(0.29) Beats \$(0.46) Estimate, Sales \$37.098M Beat \$37.05M Estimate

Financial news for CHRS dated on 2019-05-07: H.C. Wainwright Initiates Coverage On Coherus BioSciences, Inc. - Common Stock with Buy Rating, Announces \$28 Price Target

Financial news for CHRS dated on 2019-05-02: Coherus BioSciences And Amgen Settle Trade Secrets Action

Financial news for CHRS dated on 2019-05-02: Coherus BioSciences Reports Settlement Of Trade Secrets Action With Amgen

Financial news for CHRS dated on 2019-04-08: Benzinga Pro's Top 8 Most-Searchd Tickers For Morning Of Mon., Apr. 8, 2019

Financial news for CHRS dated on 2019-04-08: Coherus Biosciences shares are trading higher after the company said it expects Q1 UDENYCA net sales of \$36 million to \$38 million, well above the analyst consensus estimate.

Financial news for CHRS dated on 2019-04-05: Coherus Biosciences Will Not Disclose Topline Gross Sales, Discounts, Or Gross-To-Net Data Until Reported In Its Form 10-Q For Qtr Ended March 31

Financial news for CHRS dated on 2019-04-05: Coherus BioSciences Sees Q1 Sales \$36M-\$38M

Financial news for CHRS dated on 2019-03-28: Coherus BioSciences Management To Present At H.C. Wainwright & Co. Global Life Sciences Conference

Financial news for CHRS dated on 2019-02-28: Coherus BioSciences Q4 EPS \$(0.92) Misses \$(0.86) Estimate

Financial news for CHRS dated on 2019-01-25: Coherus BioSciences Files Patent Infringement Suit Against Amgen Related To Amgen's Humira Biosimilar

Financial news for CHRS dated on 2019-01-25: UPDATE: Coherus Says License Period In US Begins Dec. 15, 2023; Coherus Will Pay Royalties To AbbVie, But Financial Terms Not Disclosed

Financial news for CHRS dated on 2019-01-25: Coherus BioSciences Reports Global Settlement With AbbVie Which Secures Rights To Commercialize CHS-1420

Financial news for CHRS dated on 2019-01-07: Coherus Biosciences shares are trading higher after the company secured \$75 million of credit financing with HealthCare Royalty Partners.

Financial news for CHRS dated on 2019-01-07: Coherus BioSciences Secures \$75M Credit Financing With HealthCare Royalty Partners

Financial news for CHRS dated on 2018-11-30: Coherus BioSciences Announces Apexus Contract Agreement For 340B Hospitals And Clinics, And Q-Code Issuance From CMS

Financial news for CHRS dated on 2018-11-21: CMS Reportedly Posted New Reimbursement Q-Code (Q5111) For Coherus Biosciences' Udenyca

Financial news for CHRS dated on 2018-11-09: Coherus BioSciences shares are trading down 15.9% after it missed Q3 EPS estimates.

Financial news for CHRS dated on 2018-11-08: Coherus Biosciences Q3 EPS \$(0.87) Misses \$(0.77) Estimate

Financial news for CHRS dated on 2018-11-02: Coherus BioSciences Reports FDA Has

Approved Udenyca

Financial news for CHRS dated on 2018-08-29: Stocks Which Set New 52-Week High Yesterday, August 28th